Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Syngene International Ltd. ( (IN:SYNGENE) ) is now available.
Syngene International Ltd. has confirmed its expansion of biologics capabilities by adding a new ADC bioconjugation facility. This development aims to offer comprehensive services for ADCs, from discovery to GMP manufacturing, enhancing the company’s operational efficiency and market competitiveness in the biopharmaceutical sector.
More about Syngene International Ltd.
Syngene International Ltd. operates in the biopharmaceutical industry, providing integrated research, development, and manufacturing services. The company focuses on biologics, small molecules, and antibody-drug conjugates (ADCs), catering to global pharmaceutical and biotechnology companies.
Average Trading Volume: 40,265
Technical Sentiment Signal: Hold
Current Market Cap: 258.6B INR
See more insights into SYNGENE stock on TipRanks’ Stock Analysis page.